NASDAQ OMX

Notice of Extraordinary General Meeting in Karolinska Development AB (publ)

Dela

STOCKHOLM - 6 February 2017. The shareholders of Karolinska Development AB (publ), reg. no. 556707-5048 ("Karolinska Development" or the "Company") are invited to the Extraordinary General Meeting on Wednesday March 8, 2017 at 17:00 (CET), at Tomtebodavägen 23 A in Solna, Sweden.

Participation and notification of attendance

A shareholder, who wishes to participate in the meeting, must:

(i) be recorded as shareholder (not nominee registered) in the share register held by Euroclear Sweden AB on Thursday, March 2, 2017, and

(ii) notify Karolinska Development of his/her intention to attend the meeting, no later than on Thursday March 2, 2017, by telephone (+46 8 524 860 70), email (eva.montgomerie@karolinskadevelopment.com) or regular mail (Karolinska Development, "EGM", Tomtebodavägen 23 A, SE-17165 Solna, Sweden). The notification should include name, identification/registration number, address, telephone number, number of shares and, if applicable, details on proxies and number of assistants.

Nominee-registered shares

Shareholders whose shares are registered in the name of a nominee shareholder must temporarily re-register their shares in their own name in the share register kept by Euroclear Sweden AB to be allowed to participate in the meeting. The re-registration must be completed on Thursday, March 2, 2017 at the latest. Therefore, request for such registration must be made well in advance of such date.

Proxy

A shareholder attending the meeting by proxy, must issue a written proxy. The proxy is valid during the period set forth in the proxy, however, at most five years from the issuance. If a proxy is issued by a legal entity, a copy of the legal entity's registration certificate or similar document evidencing signatory powers must be enclosed. The original power of attorney and certificate of registration should be submitted to the Company by post at the address mentioned above in due time prior to the meeting. Proxy forms in Swedish and English are available for download on the Company's website, www.karolinskadevelopment.com.

Proposal for agenda

  1. Opening of the meeting
  2. Election of chairman of the meeting
  3. Preparation and approval of the voting list
  4. Approval of the agenda
  5. Election of one or two persons to verify the minutes
  6. Determination of whether the meeting has been duly convened
  7. Resolution on
    a) amendments of the Articles of Association (share capital limits and number of shares) and
    b) approval of the Board of Directors' resolution on a directed new issue of shares to the convertible holders, with payment by set-off
  8. Closing of the meeting

 

Proposals to resolutions

Item 7

a) Proposal on amendments of the Articles of Association (share capital limits and number of shares)

To enable the issue of new shares under item b) below, the limits for the share capital and the number of shares in the Articles of Association must be amended.

The Board of Directors therefore proposes that the general meeting resolves to amend the limits of the share capital from minimum SEK 13,499,743 and maximum SEK 53,998,972 to minimum SEK 25,000,000 and maximum SEK 100,000,000.

The Board of Directors also proposes that the general meeting resolves to amend the limits of the number of shares in the Articles of Association from minimum 26,999,486 and maximum 107,997,944 to minimum 50,000,000 and maximum 200,000,000.

If the general meeting resolves in accordance with the proposal, item 4, first sentence, in the Articles of Association will have the following wording:

The company's share capital shall be not less than SEK 25,000,000 and not more than SEK 100,000,000. The company shall have not less than 50,000,000 shares and not more than 200,000,000 shares.

b) Resolution on approval of the Board of Directors' resolution on a directed new issue of shares to the convertible holders, with payment by set-off (set-off issue)

The Board of Directors proposes that the general meeting resolves upon approval of the Board of Directors' resolution of 6 February 2017 on a directed new issue of B-shares to the holders of the Company's outstanding convertibles 2015/2019 on principally the following terms and conditions.

The right to subscribe for new B-shares shall, with deviation from the shareholders pre-emption rights, belong to the persons recorded as convertible holders, in the register held by Euroclear Sweden AB of the Company's outstanding convertibles 2015/2019 (the "Convertible Holders"). The purpose of the new issue of shares is to reduce the outstanding convertible debt, which would strengthen the Company's equity position compared to its share capital, thereby reducing the Company's overall financial risk profile and ensuring that its current cash resources can be used to invest in new portfolio companies. The reason for the deviation from the shareholders' pre-emption rights is that the new issue of shares by set off is a necessary part of the refinancing of the company.

The number of B-shares that each Convertible Holder shall be entitled to subscribe for shall correspond to the number of B-shares that would be issued by off-setting the Convertible Holder's claim under the Convertibles, including accrued interest until 31 December 2016, for new B-shares in the Company. The Board of Directors is, pursuant to Chapter 13, section 5, first paragraph, item 8 of the Swedish Companies Act, authorized to, before the Extraordinary General Meeting 8 March 2017, resolve the maximum amount by which the share capital shall increase, the maximum number of B-shares to be issued and the subscription price per each new B-share. The Board of Directors will, when resolving on the subscription price per each new B-share, use the following principles. The new B-shares will be issued at a subscription price corresponding to the higher of the volume weighted average share price (VWAP), of the Company's share, 90 trading days ending (i) two trading days prior to announcement of the board's resolution to convene the Extraordinary Shareholder Meeting (SEK 6.17 per share) or (ii) two trading days before the Extraordinary Shareholder Meeting.

Notification of subscription and payment by way of set-off shall be made during the period 20 March 2017 to 31 March 2017 by using an application form provided by the Company. Over-subscription is not allowed. Payment for new B-shares shall be made in connection with subscription through set-off of the Convertible Holder's claims under the convertible, including accrued interest until 31 December 2016. The new B-shares entitle to dividends for the first time on the first record date for dividend that take place after the issue of new B-shares has been registered with the Swedish Companies Registration Office and been recorded in the share register kept by Euroclear Sweden AB.

Majority requirements and conditions

Resolution under item 7 above shall be resolved upon as one decision. Such resolution requires, for its validity, support by a minimum of two-thirds of the votes cast and the shares represented.

Information at the Extraordinary General Meeting

A shareholder is entitled to require that the Board of Directors and the CEO (when possible without causing material damage to the Company) provides information regarding circumstances that may have an effect on the assessment of an item on the agenda.

Documentation

The Board of Directors' complete proposal pursuant to item 7 a) and the Board of Directors' complete resolution pursuant to item 7 b), as well as other documents according to the Swedish Companies Act will be held available at the Company's office with address Tomtebodavägen 23 A in Solna and on the Company's website, www.karolinskadevelopment.com, not later than three weeks before the meeting, i.e., not later than on Wednesday February 15, 2017. The documents will also be sent, without charge, to shareholders who so request and inform the Company of their postal address. The documents will also be held available at the Extraordinary General Meeting.

Miscellaneous

As per the date of this notice, there are 53,464,998 shares, representing a total of 66,992,880 votes in the Company, distributed among 1,503,098 shares of series A (with 15,030,980 votes) and 51,961,900 shares of series B (with 51,961,900 votes). As per the date of this notice, the Company holds 244,285 treasury shares of series B.

Solna in February 2017

Karolinska Development AB (publ )

The Board of Directors

 

 

For further information, please contact:

Jim Van heusden, CEO, Karolinska Development AB
Phone: +46 72 858 32 09, e-mail: jim.van.heusden@karolinskadevelopment.com 

Christian Tange, CFO, Karolinska Development AB    
Phone: +46 73 712 14 30, e-mail: christian.tange@karolinskadevelopment.com

 

TO THE EDITORS

About Karolinska Development AB
Karolinska Development AB is an investment company focused on identifying medical innovation and investing in the creation and growth of companies developing these assets into differentiated products that will make a difference to patients' lives and provide an attractive return on investment.

Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.

Karolinska Development has established a portfolio of 10 companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.

The Company is led by a team including investment professionals with strong venture capital backgrounds, experienced company builders and entrepreneurs, with access to a strong global network.

For more information, please visit www.karolinskadevelopment.com

 

This information is information that Karolinska Development AB (publ) (Nasdaq Stockholm: KDEV) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of Jim Van heusden, at 21.55 (CET) on February 6, 2017.


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Karolinska Development AB (publ) via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

Karolinska Development's portfolio company Aprea Therapeutics presents continued positive results from a Phase Ib/II combination study with APR-246 at hematology congress17.6.2018 06:05Pressmeddelande

STOCKHOLM, June 17, 2018. Karolinska Development's portfolio company Aprea Therapeutics presents continued positive development for the candidate drug APR-246 in patients with TP53 Mutant Myelodysplastic Syndromes (MDS) at the 2018 European Hematology Association (EHA) Annual Meeting in Stockholm. The presentation at EHA follows the positive results presented at the 2018 American Association of Cancer Research (AACR) Annual Meeting in Chicago in April. The results from the Phase Ib/II combination study with APR-246 and azacitidine show an overall response rate (ORR) of 100 per cent in 9 evaluable patients, with 8 patients achieving a complete response (CR) and 1 patient achieving a marrow complete response (mCR). Conclusive data on Median progression free survival (PFS) and overall survival (OS) have not yet been obtained in the study. Adverse Events (AEs) during the APR-246 monotherapy lead-in phase were all grade 1 or grade 2. No dose limiting toxicities have been experienced to date

Karolinska Development's portfolio company Aprea Therapeutics presents continued positive results from a Phase Ib/II combination study with APR-246 at hematology congress17.6.2018 06:05Pressmeddelande

STOCKHOLM, June 17, 2018. Karolinska Development's portfolio company Aprea Therapeutics presents continued positive development for the candidate drug APR-246 in patients with TP53 Mutant Myelodysplastic Syndromes (MDS) at the 2018 European Hematology Association (EHA) Annual Meeting in Stockholm. The presentation at EHA follows the positive results presented at the 2018 American Association of Cancer Research (AACR) Annual Meeting in Chicago in April. The results from the Phase Ib/II combination study with APR-246 and azacitidine show an overall response rate (ORR) of 100 per cent in 9 evaluable patients, with 8 patients achieving a complete response (CR) and 1 patient achieving a marrow complete response (mCR). Conclusive data on Median progression free survival (PFS) and overall survival (OS) have not yet been obtained in the study. Adverse Events (AEs) during the APR-246 monotherapy lead-in phase were all grade 1 or grade 2. No dose limiting toxicities have been experienced to date

INVNT/IP: US Responds to Nation-sponsored Crown-jewel Intellectual Property Theft15.6.2018 23:34Pressmeddelande

US Announcement of Large-Scale Tariffs in Response to Chinese Crown-Jewel Intellectual Property Theft Lauded by IP Protection Consortium INVNT/IP SEATTLE, June 15, 2018 (GLOBE NEWSWIRE) -- The Trump administration today announced 25% tariffs on $50 billion in Chinese goods, representing the first time the United States government has marked sectors in US-China trade for retaliation as a response to theft of crown-jewel intellectual property. In a public statement, President Trump announced that the measures were targeted toward goods that "contain industrially significant technologies." US Trade Representative Robert Lighthizer applauded the move on Fox News, noting, "It's thorough. It's moderate. It's appropriate." In a further explanation of the move, he added, "What I want to do is make sure that we protect our technology here at home, that we stop cybertheft and forced technology transfer, and ultimately, remember: 'China 2025' is a $300 billion subsidy program. The United States h

Brookfield Asset Management Announces Results of Annual and Special Meeting of Shareholders15.6.2018 22:30Pressmeddelande

BROOKFIELD, NEWS, June 15, 2018 (GLOBE NEWSWIRE) -- Brookfield Asset Management Inc. (TSX:BAM.A) (NYSE:BAM) (Euronext:BAMA) today announced that at the company's annual and special meeting of shareholders held earlier today in Toronto, approximately 92% of Class A Limited Voting Shares ("Class A Shares") voted in favour of an advisory vote approving the company's approach to executive compensation. In addition, at the meeting all eight nominees proposed for election to the board of directors by holders of Class A Shares and all eight nominees proposed for election to the board of directors by the holder of Class B Limited Voting Shares ("Class B Shares") were elected. Detailed results of the vote for the election of directors are set out below. Management received the following proxies from holders of Class A Shares in regard to the election of the eight directors nominated by this shareholder class: Director Nominee Votes For % Votes Withheld % M. Elyse Allan 620,669,437 99.53 2,921,9

NEP Completes Acquisition of Telerecord15.6.2018 13:53Pressmeddelande

FLORENCE, Italy, June 15, 2018 (GLOBE NEWSWIRE) -- Today NEP Group, a leading outsourced technical production partner supporting premier content producers of live sports and entertainment, announced that it has completed its acquisition of Telerecord, an Italy-based provider of outside broadcast solutions. Telerecord, a local industry leader with strong client relationships, covers popular sporting events in Italy and throughout Southern Europe including football, ice hockey and bobsleigh. The deal further diversifies NEP's business and expands its reach in Europe by adding additional local resources and talent. As part of the deal, all Telerecord staff members will join NEP. Telerecord will be rebranded as NEP and will be part of NEP Italy, which is led by Sergio Cecchini, GM of NEP Italy, who joined NEP in May. Telerecord also brings a fleet of several outside broadcast trucks, sprinter vans and motorcycles to the NEP Worldwide Network to serve clients across Europe. "We couldn't be

Fortuna Reports Results of Annual General Meeting15.6.2018 11:00Pressmeddelande

VANCOUVER, British Columbia, June 15, 2018 (GLOBE NEWSWIRE) -- Fortuna Silver Mines Inc. (NYSE:FSM) (TSX:FVI) hereby announces the voting results at the Company's annual general meeting held on June 14, 2018. A total of 108,538,241 common shares were represented at the meeting, being 68% of the Company's issued and outstanding shares. Shareholders voted in favour of all matters brought before the meeting including the appointment of auditors, the election of management's nominees as directors, and the ratification and approval of the Company's amended Advance Notice Policy. Detailed results of the votes on the election of directors are as follows: Director Votes For Votes Withheld Jorge Ganoza Durant Simon Ridgway Mario Szotlender David Farrell David Laing Alfredo Sillau Kylie Dickson 74,947,635 (97.4%) 63,448,600 (82.5%) 70,831,225 (92.1%) 74,816,864 (97.3%) 73,597,731 (95.7%) 75,716,342 (98.4%) 76,476,115 (99.4%) 1,930,230 (2.5%) 13,429,266 (17.4%) 6,046,640 (7.9%) 2,061,001 (2.7%) 3

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum